Avanir Pharmaceuticals achieved positive results from its Phase III trial evaluating Zenvia, an NMDA antagonist and sigma-1 agonist, in diabetic neuropathic pain. The primary endpoint of the trial was based on the daily diary entries for the Pain Rating Scale as defined in the FDA’s SPA. In the trial, two doses of Zenvia, 45/30 mg DMQ and 30/30 mg DMQ dosed twice daily, were compared to placebo based on patient diary entries for the Pain Rating Scale. Both Zenvia treatment groups had ...